Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vita Life SciencesASX:VLS +1.61%78 3-Year EBITDA Growth Rate is 9.60% as of Dec. 2025, which is 21% below its 10-year median of 12.20. GuruFocus rates ASX:VLS with a GF Score™ of 78/100 and a GF Value™ of A$2.49 (Fairly Valued). The stock has 1 warning sign investors should review. Among 814 Drug Manufacturers companies, Vita Life Sciences ranks better than 51.97% on this metric.
During the past 12 months, Vita Life Sciences's average EBITDA Per Share Growth Rate was 14.90% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 9.60% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 8.60% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 12.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Vita Life Sciences was 147.50% per year. The lowest was -9.80% per year. And the median was 12.20% per year.
Vita Life Sciences (ASX:VLS) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Vita Life Sciences 3-Year EBITDA Growth Rate Related Terms
ASX:VLS vs ZTS, UTHR: 3-Year EBITDA Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Vita Life Sciences's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vita Life Sciences 3-Year EBITDA Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Vita Life Sciences's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Vita Life Sciences's 3-Year EBITDA Growth Rate falls into.
Vita Life Sciences 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 9.60% mean?
Vita Life Sciences (ASX:VLS) has a 3-Year EBITDA Growth Rate of 9.60% as of Dec. 2025. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Vita Life Sciences and its competitors. This is 21% below median its historical median of 12.20. According to the industry distribution chart, Vita Life Sciences ranks #391 out of 814 companies in the Drug Manufacturers industry, placing it in the top 48%.
Is Vita Life Sciences' 3-Year EBITDA Growth Rate too high?
Vita Life Sciences' current 3-Year EBITDA Growth Rate of 9.60% is 21% below median its 10-year median of 12.20. The Drug Manufacturers industry median 3-Year EBITDA Growth Rate is 8.90. Vita Life Sciences' value of 9.60% is 7.9% above this industry median. Based on the distribution chart, Vita Life Sciences ranks #391 out of 814 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Vita Life Sciences has a GF Score™ of 78/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Vita Life Sciences' 3-Year EBITDA Growth Rate compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Vita Life Sciences ranks #391 out of 814 companies for 3-Year EBITDA Growth Rate. This puts Vita Life Sciences in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 8.90. Vita Life Sciences' value of 9.60% is 7.9% above this benchmark. While the company's 10-year median is 12.20 vs. the industry median of 8.90, Vita Life Sciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Drug Manufacturers company?
The median 3-Year EBITDA Growth Rate among Drug Manufacturers companies is 8.90, based on 814 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vita Life Sciences's current 3-Year EBITDA Growth Rate of 9.60% is 7.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Vita Life Sciences and its competitors. For the Drug Manufacturers industry, the median 3-Year EBITDA Growth Rate is 8.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vita Life Sciences's current 3-Year EBITDA Growth Rate is 9.60%, which is 21% below median its own 10-year median of 12.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vita Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, Vita Life Sciences (ASX:VLS) is currently considered Fairly Valued. The stock's GF Value™ is A$2.49, compared to a current price of A$2.52 — trading 1.2% above its estimated fair value. The current 3-Year EBITDA Growth Rate is 9.60%, which is 21% below median its 10-year median of 12.20 and 7.9% above the Drug Manufacturers industry median of 8.90. Vita Life Sciences' overall GF Score™ is 78/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Vita Life Sciences (ASX:VLS), the current 3-Year EBITDA Growth Rate is 9.60% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vita Life Sciences (ASX:VLS) Overvalued in 2026?
Based on GuruFocus' analysis, Vita Life Sciences stock appears to be overvalued.
The current stock price of A$2.52 is trading 1.2% above its estimated GF Value™ of A$2.49.
GuruFocus considers Vita Life Sciences to be Fairly Valued.
Key valuation signals for ASX:VLS:
3-Year EBITDA Growth Rate: 9.60% (21% below median its 10-year median of 12.20)
GF Value™: A$2.49 vs. price of A$2.52 (1.2% above fair value)
Industry Position: 7.9% above the Drug Manufacturers median (#391 of 814)
No single metric tells the full story. See the ASX:VLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vita Life Sciences Ltd is an Australian-based pharmaceutical and healthcare company involved in formulating, packaging, selling, and distributing vitamins and supplements. It produces a wide range of premium supplements, vitamins, minerals, herbs, and superfoods catered to all age categories and health conditions. The company markets its products through pharmacies and health food stores under the VitaHealth, VitaScience, and Herbs of Gold brands throughout the Asia-Pacific region. Vita Life Sciences has two operating segments: VMS Operational, which generates maximum revenue, and VMS Investments. Geographically, the Group generates maximum revenue from Malaysia and Singapore, and the rest from Australia, and China and Vietnam.
78GF Score
Get the complete analysis for ASX:VLS
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:VLS has been successfully added to your 
